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INTRODUCTION
Cervical carcinoma is the most common gynecologi-
cal malignancy and the second most common malig-
nancies in women worldwide. Data from the Depart-
ment of Anatomical Pathology Faculty Of Medicine,
Sriwijaya University RSMH Palembang also places
cervical carcinoma as the second most common ma-
lignancy in women, after breast malignancy.1-4
Although the role of HPV in cervical cancer car-
cinogenesis has been proven, only a few of HPV in-
fection will develop into cervical carcinoma. This sug-
gests possibility of other influences that might be in-
volved in the development of cervical carcinoma, one
of them is genetic factor. Mutation of the p53 gene
is one of the genetic variations associated with the
occurrence of malignancy.5-7
P53 gene is a tumor suppressor gene that plays a
role in response to stress in order to maintain geno-
mic stability, responds to DNA damage, hypoxia,
metabolic stress and activation of oncogenes. Single
nucleotide polymorphisms (SNPs) of p53 gene co-
don 72 will produce two types of alleles, namely Ar-
ginine (p53-R72) or Proline (p53-P72) at the struc-
ture of the amino acid at codon 72. According to
Storey, women who are homozygous for Arginine at
codon 72 of p53 gene are seven times more likely to
be exposed to cervical cancer.6,9-11
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Abstrak
Tujuan: Mengetahui hubungan antara polimorfisme gen p53 kodon 72
dan karsinoma serviks.
Metode: Penelitian observasional analitik dengan desain studi kasus-
kontrol. Dilakukan dari November 2013 sampai dengan Maret 2014
bertempat di Departemen Obstetri dan Ginekologi Rumah Sakit Dr.
Mohammad Hoesin Palembang dan Laboratorium Mikrobiologi Ru-
mah Sakit Dr. Moh. Hoesin Palembang.
Hasil: Penelitian diikuti oleh 100 subjek yang memenuhi kriteria inklusi,
masing-masing 50 subjek pada kelompok kasus dan kontrol. Distribusi
genotipe gen p53 kodon 72 pada kelompok kasus adalah Arg/Arg 54%,
Pro/Arg 42% dan Pro/Pro 4% sedangkan pada kelompok kontrol Arg/Arg
36%, Pro/Arg 46% dan Pro/Pro 18%. Genotip Arg/Arg memiliki risiko
6,7 kali lebih besar untuk terjadi karsinoma serviks dibandingkan dengan
genotip Pro/Pro. Adanya alel Arg pada gen p53 kodon 72 meningkatkan
risiko terjadinya karsinoma serviks 2,6 kali lebih besar dibandingkan alel
Pro.
Kesimpulan: Mutan Prolin menjadi Arginin pada polimorfisme gen p53
P72R merupakan faktor risiko terjadinya karsinoma serviks.
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Comparative sequence analysis of non-human
primates demonstrated that p53-P72 is the wild
type, although the number of p53-R72 population
is quite enough (>50%). The frequency of ho-
mozygous Arginine in certain ethnicity is between
12.4% and 53.4%. Beckman and his colleagues were
the first to demonstrate the difference in allele fre-
quency distribution between the R72 and P72 in Ni-
gerian population (black Africans) and Sweden
(Europe West), amounting 17 percents and 63 per-
cents of the population.6,9,11-12
Variation of the allele frequency in some ethnici-
ties may cause differences in research result about
relationship between p53 codon 72 polymorphism
and cervical carcinoma in several countries. Research
in Sweden, Chile, Peru, China and India supported
these findings.5,8,13-16 However, studies in Nether-
lands, USA, Poland, Italy, Korea, Japan and Thai-
land are contradictory.17-26 In Palembang, there is
no data about codon 72 allele of the p53 gene and
its association with carcinoma of the cervix, so it is
necessary to identify the association between p53
codon 72 polymorphism and cervical carcinoma in
Palembang population.
METHOD
This is an analytical observational research with case
control study design. This study is conducted at the
Department of Obstetrics and Gynecology and Mi-
crobiology Laboratory of Faculty of Medicine Sri-
wijaya University in Dr. Mohammad Hoesin Hos-
pital Palembang, which started from November 1st
2013 until March 31st 2014.
Populations of this study are patients who are
diagnosed with cervical carcinoma who came to the
outpatient clinic and any hospitalized patient in
obstetric and gynecology department of RSMH
Palembang. Sampling is done by quota sampling
technique, until total subjects in the experimental
group and control group reach 50 patients.
The inclusion criteria for the experimental group
are patients who are diagnosed with cervical carci-
noma, which is proved by histopathology result and
patient’s willingness to join the research by signing
the informed consent form. For the control group,
inclusion criteria are patients who came to gyneco-
logy outpatient clinic or who has been hospitalized
in in-patient installation of obstetric and gynecology
department of RSMH Palembang who is not diag-
nosed or suspected to have neoplasm or another
malignancy diseases, no precancerous lesion Pap
Smear examination or suspected to have cervical car-
cinoma and patient’s willingness to join the research
by signing the informed consent form.
Exclusion criteria for case group are patients who
have been diagnosed or suspected to have other ma-
lignancy or if patient are not willing to join the re-
search. For the control group, criteria were pre-
cancerous lesion in Pap’s Smear result or suspected
cervical carcinoma patients who refuse to join the
research.
RESULT
Table 1 shows the socio-demographic and clinical
characteristic of research subjects.
Table 1. Socio-demographic and Clinical Characteristic.
Characteristic Case Control p
Median age 49 ± 8.8 38.8 ± 9.5 < 0.0001
Median BMI 23.22 ± 4.90 21.64 ± 31.08 0.058
Domicile
Urban area 31 41 0.03
Rural area 19 9
Ethnic group
Sumatera 33 42 0.038
Non-Sumatera 17 8
Education
Uneducated 5 0 < 0.0001
Elementary 14 1
Junior high 14 6
Senior high 16 22
Bachelor 1 21
Occupation
Housewife 38 22 < 0.0001
Civil servant 1 27
Others 11 1
Smoking history
Yes 2 2 1.00
No 48 48
Contraception
history Oral
Yes 9 4 0.23
No 41 46
First sexual activity
< 20 years old 33 8 < 0.001
≥ 20 years old 17 42
Marriage history
1 time 6 2 0.27
> 1 time 44 48
Parity total
≥ 7 8 0 < 0.001
< 7 42 50
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The youngest age in this research is 19 years old
and the oldest subject is 73 years old. There is a
significant difference in median age, domicile distri-
bution, ethnic group and occupation between the
case and control group.
Age of first sexual activity and total parity are
important clinical risk factors for cervical carcinoma.
However smoking, oral contraception, and marriage
status showed no significant correlation with the in-
cidence of cervical carcinoma. The clinical charac-
teristics of the research subjects are presented on
the table above.
In this research gene p53 codon 72 is obtained
through DNA extraction process and PCR-RFLP
method from blood sample. Polymorphism in gene
p53 codon 72 is recognized with BstUI enzyme.
Figure 1 showing the PCR-RFLP result example.
Genotype appearance of wild type Pro/Pro (1 band
with fragment length 199 bp) is showed in subject
number 46. Subject number 50 has mutant genotype
Arg/Arg (2 bands with fragment length 113 bp and
86 bp). Subject number 47, 48 and 49 exhibit mutant
heterozygote genotype appearance of Pro/Arg (3
bands with fragment lengths of 199 bp, 113 bp and
86 bp).
Genotype distribution in case group is Arg/Arg
54%, Pro/Arg 42% and Pro/Pro 4%. The distribu-
tion of genotype in control group is Arg/Arg 36%,
Pro/Arg 46% and Pro/Pro 18%. In general, the dis-
tribution of genotype Arg/Arg, Pro/Arg and
Pro/Pro are 45%, 44% and 11% respectively. From
the whole subjects, Arg allele percentage is 67% and
Pro allele is 33%.
Statistic analysis with Chi square test is done to
determine the correlation between polymorphism
gene p53 codon 72 and cervical carcinoma. There is
a significant increase in the risk of cervical carci-
noma for individual with homozygote mutant geno-
type (Arg/Arg) compared with individual with wild
type genotype (Pro/Pro) on gene p53 codon 72
(p=0.013; OR 6.75; 95% CI 1.34-34.94). Allele
analysis showed women who has Arginine allele in
the p53 gene codon 72 is at risk of cervical cancer
2,6 times greater than women with Proline allele
(OR 2.61; 95% CI 1.40-4.88).
Table 2. Correlation of Genotype p53 Gene Codon 72 
      and Carcinoma Cervix
Case Control
p
N % N %
Genotype Arg/Arg 27 54 18 36 0.013*
      Pro/Arg 21 42 23 46 0.097**
      Pro/Pro 2 4 9 18 Ref
    Total 29 100 27 100
DISCUSSION
Epidemiological data shows that most cervical car-
cinoma is found in young women. Median age of
this finding is 52 years old with distribution peak
at age of 35-39 years old and 60-64 years old.1,3
Concurrent with previous literature, median age of
the case group (cervical carcinoma) in this research
is 49.8 ± 8.8 years old.
In this research, there is a significant difference
in domicile, education level, job and ethnic group
between case group and control group. Whereas
median body mass index (BMI) in this research sub-
ject found no differences between both groups.
Socioeconomic factor is related with carcinoma cer-
vix. The majority of carcinoma cervix patients came
from low socioeconomic who has no access to rou-
tine gynecology examination.1,3 Reis et al discovered
that individual with high education level has lower
risk of cervical carcinoma(OR 0.18). They suggested
that low education level is related with an increase
of sexual activity on young age, numerous sexual
partners and bad genital hygiene.27
Statistically in this research there is no significant
correlation between smoking history and cervical
carcinoma. This result is different with meta-analy-
sis about correlation between smoking and cervical
carcinoma by Gandini et all. They concluded that
active smokers are at increased risk of contracting
cervical squamous cell carcinoma (RR 2.03; 95% CI
1.31-4.04), whereas risk among ex-smoker is rela-
tively lower at 1.80 (95% CI 0.95-3.44).28
Figure 1. Example of PCR-RFLP Result Gene p53 Codon
72 with BstUI Restriction Enzyme.
Vol 3, No 3
July 2015 p53 Gene Codon 72 Polymorphisms  167
Reproductive history is also affects the risk of
cervical carcinoma. Analysis result in this research
also shows significant correlation between parity ≥7
and cervical carcinoma (p=0.006). Women who has
parity ≥7 times has 2 times the risk to have carci-
noma cervix (OR 2.19; 95% CI 1.75-2.74).
Median age of first sexual activity in the case
group in this research is 19.12±3.98 years old. This
median age is lower than the control group. Statis-
tical analysis shows an increased risk of cervical car-
cinoma 10 times higher than women who have their
first sexual activity before the age of 20 is 10.19
(95% CI 3.92-26.51).
Oral contraception combination pill usage can be
a risk factor of cervical carcinoma. Research from
Moreno et all show an odds ratio of 2.82 (95% CI
1.46-5.42) for contraception usage 5-9 years and 4.03
(95% CI 2.09-8.02) for usage ≥10 years.1,3,27,29,30
However in this research, there is no significant cor-
relation between oral contraception and cervical car-
cinoma (p=0.23).
Comparative sequence analysis to primate except
human shows that p53-R72 is a wild type, even
though p53-R72 in population is varied (>50%).
Data from various ethnicities shows Arginine ho-
mozygous frequency is between 12.4% till
53.4%.6,9,27,31 Genotype distribution pattern and al-
lele in this research is similar with Andersson’s re-
search in Sweden and Ojeda’s in Chile; the only dif-
ference is the lower genotype distribution of wild
type.5,13
Chi square test done between gene genotype p53
codon 72 and cervical carcinoma concludes that there
is an increasing risk of cervical carcinoma 6.7 times
for individual with homozygote mutant genotype
(Arg/Arg) compared with individual with wild type
genotype (Pro/Pro) for gene p53 codon 72 (OR 6.75;
95% CI 1.34-34.94). Individuals with heterozygote
mutant genotype (Pro/Arg) have no significant risk
when compared with women with wild type geno-
type (p=0.079). Allele analysis shows significant re-
sult for allele Arg to p53 gene codon 72, which will
increase the risk of carcinoma cervix 2.61 times higher
than allele Pro (p=0.02; OR 2.61; 95% CI 1.40-4.88).
Some of supporting researches have various odds
ratio (OR) result. Meta-analysis by Jee et al in 2004
shows that the odds ratio (OR) of women with cer-
vical carcinoma with homozygote mutant (Arg/ Arg)
compared with heterozygote mutant (Arg/ Pro) in
general is 1.2 (1.1-1.3; p<0.001).32
Some of the researches also relates polymorphism
p53 codon 72 with prognosis and response to the-
rapy. Individual with genotype R72 has a higher risk
and better quality of life after receiving chemother-
apy or radiation therapy. Similar results are also
found in cancer of head and neck, breast and lung.9
CONCLUSION
Proline mutation to Arginine in gene p53 P72R is
a risk factor for cervical carcinoma.
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